GLP-1 & Incretin Research Hub
GLP-1 agonists and dual/triple incretin agonists are among the most clinically significant peptide-class medicines of the past decade — and among the most heavily marketed online. This hub explains the science and the regulatory frame, without promoting or instructing use.
Incretin receptor biology
GLP-1, GIP, glucagon receptor basics; pharmacology overview; clinical relevance; regulatory sensitivity.
GLP-1 vs GIP vs glucagon receptors
Receptor comparison, mechanistic differences, and how dual / triple agonists differ in their pharmacological profile.
Weight-loss medicine advertising caution (UK)
Why prescription-only weight-loss medicines cannot be advertised to the public in the UK, and why PeptideStacks avoids promotional framing.
Clinical-trial evidence vs online claims
How the trial evidence base actually reads, and why online claims often outrun what the trials support.